Cargando…
Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB–III non‐small cell lung cancer patients using radiomic features
BACKGROUND: To develop a radiomics model based on chest computed tomography (CT) for the prediction of a pathological complete response (pCR) after neoadjuvant or conversion chemoimmunotherapy (CIT) in patients with non‐small cell lung cancer (NSCLC). METHODS: Patients with stage IB–III NSCLC who re...
Autores principales: | Yang, Nong, Yue, Hai‐Lin, Zhang, Bai‐Hua, Chen, Juan, Chu, Qian, Wang, Jian‐Xin, Yu, Xiao‐Ping, Jian, Lian, Bin, Ya‐Wen, Liu, Si‐Ye, Liu, Jin, Zeng, Liang, Yang, Hai‐Yan, Zhou, Chun‐Hua, Jiang, Wen‐Juan, Liu, Li, Zhang, Yong‐Chang, Xiong, Yi, Wang, Zhan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542462/ https://www.ncbi.nlm.nih.gov/pubmed/37596822 http://dx.doi.org/10.1111/1759-7714.15052 |
Ejemplares similares
-
Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022) -
Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non‐small cell lung cancer
por: Hong, Tao, et al.
Publicado: (2021) -
Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021) -
A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer
por: Liu, Wei, et al.
Publicado: (2022) -
Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)